A number of other research firms also recently weighed in on ZIOP. HC Wainwright reaffirmed a buy rating and issued a $5.50 price target on shares of ZIOPHARM Oncology in a research note on Thursday, May 9th. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a buy rating to a hold rating in a research note on Saturday, May 18th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. ZIOPHARM Oncology presently has an average rating of Buy and a consensus price target of $5.75.
NASDAQ ZIOP opened at $5.05 on Tuesday. ZIOPHARM Oncology has a 1-year low of $1.56 and a 1-year high of $7.25. The company has a current ratio of 8.89, a quick ratio of 8.89 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $840.95 million, a PE ratio of -10.52 and a beta of 2.60. The firm’s fifty day simple moving average is $5.84 and its 200-day simple moving average is $4.42.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Aperio Group LLC bought a new stake in ZIOPHARM Oncology in the second quarter worth $35,000. Harel Insurance Investments & Financial Services Ltd. bought a new stake in ZIOPHARM Oncology in the first quarter worth $35,000. Magnus Financial Group LLC bought a new stake in ZIOPHARM Oncology in the first quarter worth $39,000. Mercer Global Advisors Inc. ADV bought a new stake in ZIOPHARM Oncology in the first quarter worth $48,000. Finally, Niemann Capital Management Inc. bought a new stake in ZIOPHARM Oncology in the second quarter worth $79,000. 38.94% of the stock is currently owned by institutional investors and hedge funds.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.